Investments
7Portfolio Exits
2About BELLE Capital
Belle Capital is an early stage angel fund focused on building companies in Michigan, the Midwest and other underserved geographic markets. Belle Capital looks for capital efficient companies with a unique product or service filling an urgent market need and targets the mobile/internet/IT, technology-enabled services, life sciences/medical devices, advanced manufacturing and CleanTech market sectors. Companies seeking Belle Capital's investments must have at least one female founder or C-level exec, and/or be willing to recruit top female talent to the C-suite and Board of Directors.
Want to inform investors similar to BELLE Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest BELLE Capital News
Jun 15, 2021
Back to HomeHOUSTON, TX, Hello Alice announced a $21 million Series B raise led by QED Investors.Hello Alice, a machine learning platform connecting small business owners to capital, networks and business services, announced a $21 million Series B raise led by QED Investors with participation from new investors including Backstage Capital, Green Book Ventures, Harbert Growth Partners, and How Women Invest.The full list of Series B investors in as follows: Backstage Capital, Blue Ivy, Cathie Reid, BCO Venture Fund, Belle Capital, Jacki Zehner, Jake Hastings, Harbert Growth Partners, How Women Invest, Golden Seeds, Green Book Ventures, Jean Case, Lovell Family, QED Investors, Ring Fund, Shatter Fund, Signia Venture Partners, and Silicon Valley Bank. Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.
BELLE Capital Investments
7 Investments
BELLE Capital has made 7 investments. Their latest investment was in Ocuphire Pharma as part of their Series A on July 7, 2019.
BELLE Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
7/22/2019 | Series A | Ocuphire Pharma | $5M | Yes | 10 | |
5/10/2019 | Series A - II | |||||
1/26/2018 | Unattributed VC | |||||
12/22/2017 | Series A | |||||
3/26/2015 | Series A - II |
Date | 7/22/2019 | 5/10/2019 | 1/26/2018 | 12/22/2017 | 3/26/2015 |
|---|---|---|---|---|---|
Round | Series A | Series A - II | Unattributed VC | Series A | Series A - II |
Company | Ocuphire Pharma | ||||
Amount | $5M | ||||
New? | Yes | ||||
Co-Investors | |||||
Sources | 10 |
BELLE Capital Portfolio Exits
2 Portfolio Exits
BELLE Capital has 2 portfolio exits. Their latest portfolio exit was Cardialen on December 14, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/14/2022 | Acquired | 2 | |||
Date | 12/14/2022 | |
|---|---|---|
Exit | Acquired | |
Companies | ||
Valuation | ||
Acquirer | ||
Sources | 2 |
BELLE Capital Team
1 Team Member
BELLE Capital has 1 team member, including current Managing Partner, Lauren Flanagan.
Name | Work History | Title | Status |
|---|---|---|---|
Lauren Flanagan | Managing Partner | Current |
Name | Lauren Flanagan |
|---|---|
Work History | |
Title | Managing Partner |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
